Airway Inflammation and Airflow Limitation in COPD

Author(s): Diahn-Warng Perng, Kang-Cheng Su, Lung-Yu Liu

Journal Name: Current Respiratory Medicine Reviews

Volume 2 , Issue 4 , 2006

Become EABM
Become Reviewer
Call for Editor


The Global Initiative for Chronic Obstructive Lung Disease guidelines stated that COPD is a disease of airflow limitation that is associated with abnormal inflammatory response. Targeting inflammation and improving airflow is a central goal to treat this disease. Corticosteroids are currently the most popular anti-inflammatory agents for obstructive airway disease. Several long-acting bronchodilators are available to improve airflow. Suppression of inflammation in the asthmatic airway is associated with an increase of expiratory flow. In COPD, the relation between inflammation and airflow limitation is not as clear as that in asthma. Understanding the characters of inflammation and the pathogenesis of airflow limitation may help to provide optimal treatment for patients with COPD.

Keywords: Neutrophils, anti-inflammatory, corticosteroids, T Lymphocytes, matrix metalloproteases, bronchodilator reversibility

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [419 - 426]
Pages: 8
DOI: 10.2174/157339806778777267
Price: $65

Article Metrics

PDF: 2